Company / Cost of Revenue
TENAX THERAPEUTICS, INC. Cost of Revenue History
FY2012-FY2016 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$129.8K
FY2016
5-year range
$43.1K / $129.8K
FY2012-FY2016
Trend
+0.0%
vs FY2015
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $43,111 to $129,800 over the past 2 years.
Based on SEC 10-K filings.
$129,800 in FY2016 with a 3-year CAGR of +36.3%.
Increased from $43,111 to $129,800 over the past 2 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +36.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +36.3%, indicating consistent growth.
- In FY2016, cost of revenue increased 0.0% year-over-year.
- Peak cost of revenue was recorded in FY2012.
- Lowest cost of revenue in the period was in FY2014.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.24 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2016 | $129.8K | +0.0% |
| FY2015 | $129.8K | +201.1% |
| FY2014 | $43.1K | -15.9% |
| FY2013 | $51.3K | -76.6% |
| FY2012 | $219.2K | - |
As of FY2016 · SEC 10-K · Updated Jun 28, 2026